Immunotherapy clinical trials

Explore recruiting immunotherapy clinical trials.

Recruiting immunotherapy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunotherapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing extensive curative surgery and radiotherapy: Matisse-2

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors: the SERPENTINE clinical trial (Single cEll pRofiling PErsistaNce To ImmuNothErapy)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective, open-label study to analyze the efficacy and safety of low-dose oral immunotherapy in children with severe IgE-mediated cow's milk allergy treated with omalizumab. ILO study.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2403 BI-MAPS Assessment of ivonescimab as salvage treatment in relapsing pleural mesothelioma patients, previously treated by immunotherapy and standard chemotherapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Immunotherapy trials by city

Immunotherapy in Toronto Immunotherapy in Vancouver Immunotherapy in Montreal Immunotherapy in Calgary Immunotherapy in Edmonton Immunotherapy in Ottawa Immunotherapy in Winnipeg Immunotherapy in Quebec City Immunotherapy in Hamilton Immunotherapy in Kitchener Immunotherapy in London Immunotherapy in Halifax Immunotherapy in New York Immunotherapy in Los Angeles Immunotherapy in Chicago Immunotherapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease